Disease · MONDO_0024880

metastatic malignant neoplasm

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. metastatic malignant neoplasm. Diseases, record MONDO_0024880. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0024880

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: metastatic malignant neoplasm; Open Targets
Open Targets ID: MONDO_0024880; Open Targets
Other names: malignant metastatic neoplasm, metastatic cancer, metastatic neoplasm, malignant; Open Targets
NCI Thesaurus: C36263; NCI Thesaurus
Highest stage of its drugs: Approval, for 1 of its 74 drugs, from TTD; Open Targets

Drugs74

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
IRSOGLADINE	CHEMBL136497	Small molecule	Approval	TTD	1	0	0	Drugs and targets
PEMBROLIZUMAB	CHEMBL3137343	Antibody	Phase 3	ClinicalTrials.gov	6	6	5	Drugs and targets
NIVOLUMAB	CHEMBL2108738	Antibody	Phase 3	ClinicalTrials.gov	4	4	3	Drugs and targets
ATEZOLIZUMAB	CHEMBL3707227	Antibody	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
IPILIMUMAB	CHEMBL1789844	Antibody	Phase 3	ClinicalTrials.gov	3	3	2	Drugs and targets
BALSTILIMAB	CHEMBL4297877	Antibody	Phase 3	ClinicalTrials.gov	2	2	0	Drugs and targets
CAMRELIZUMAB	CHEMBL4297715	Antibody	Phase 3	ClinicalTrials.gov	2	2	0	Drugs and targets
CEMIPLIMAB	CHEMBL4297723	Antibody	Phase 3	ClinicalTrials.gov	2	2	0	Drugs and targets
SINTILIMAB	CHEMBL4297829	Antibody	Phase 3	ClinicalTrials.gov	2	2	0	Drugs and targets
SYM-021	CHEMBL4298114		Phase 3	ClinicalTrials.gov	2	2	0	Drugs and targets

1 to 10 of 74

See all 74 drugs

Targets125

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
PDCD1	Programmed cell death protein 1	9	Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor	Phase 3	https://conductscience.org/library/genes/5133	Drugs and targets
RRM1	Ribonucleoside-diphosphate reductase RR1	4	Ribonucleoside-diphosphate reductase RR1 inhibitor	Phase 2	https://conductscience.org/library/genes/6240	Drugs and targets
RRM2	Ribonucleoside-diphosphate reductase RR1	4	Ribonucleoside-diphosphate reductase RR1 inhibitor	Phase 2	https://conductscience.org/library/genes/6241	Drugs and targets
RRM2B	Ribonucleoside-diphosphate reductase RR1	4	Ribonucleoside-diphosphate reductase RR1 inhibitor	Phase 2	https://conductscience.org/library/genes/50484	Drugs and targets
POLA1	DNA polymerase (alpha/delta/epsilon)	3	DNA polymerase (alpha/delta/epsilon) inhibitor	Phase 2	https://conductscience.org/library/genes/5422	Drugs and targets
POLA2	DNA polymerase (alpha/delta/epsilon)	3	DNA polymerase (alpha/delta/epsilon) inhibitor	Phase 2	https://conductscience.org/library/genes/23649	Drugs and targets
POLD1	DNA polymerase (alpha/delta/epsilon)	3	DNA polymerase (alpha/delta/epsilon) inhibitor	Phase 2	https://conductscience.org/library/genes/5424	Drugs and targets
POLD2	DNA polymerase (alpha/delta/epsilon)	3	DNA polymerase (alpha/delta/epsilon) inhibitor	Phase 2	https://conductscience.org/library/genes/5425	Drugs and targets
POLD3	DNA polymerase (alpha/delta/epsilon)	3	DNA polymerase (alpha/delta/epsilon) inhibitor	Phase 2	https://conductscience.org/library/genes/10714	Drugs and targets
POLD4	DNA polymerase (alpha/delta/epsilon)	3	DNA polymerase (alpha/delta/epsilon) inhibitor	Phase 2	https://conductscience.org/library/genes/57804	Drugs and targets

1 to 10 of 125

See all 125 targets

Trials36

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 2 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00670748	Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic Cancer	Phase 2	45	2016-06-27	Metastatic Melanoma, Metastatic Renal Cell Cancer, Metastatic Cancer	ALDESLEUKIN, CYCLOPHOSPHAMIDE, FLUDARABINE PHOSPHATE	Its record names the disease	ClinicalTrials.gov
NCT02919696	A Study of Abemaciclib (LY2835219) in Native Chinese Participants With Advanced and/or Metastatic Cancers	Phase 1	26	2020-09-25	Advanced Cancer, Metastatic Cancer	ABEMACICLIB	Its record names the disease	ClinicalTrials.gov
NCT01218867	CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer	Phase 1/2	24	2016-07-22	Metastatic Cancer, Metastatic Melanoma, Renal Cancer	ALDESLEUKIN, CYCLOPHOSPHAMIDE, FLUDARABINE	Its record names the disease	ClinicalTrials.gov
NCT02111850	T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive	Phase 1/2	21	2022-03-29	Cervical Cancer, Renal Cancer, Urothelial Cancer, Melanoma, Breast Cancer	ALDESLEUKIN, CYCLOPHOSPHAMIDE, FLUDARABINE	Its record names the disease	ClinicalTrials.gov
NCT00704938	Gene-Modified Lymphocytes, High-Dose Aldesleukin, and Vaccine Therapy in Treating Patients With Progressive or Recurrent Metastatic Cancer	Phase 2	3	2012-08-14	Kidney Cancer, Melanoma (Skin), Unspecified Adult Solid Tumor, Protocol Specific	ALDESLEUKIN	Its record names the disease	ClinicalTrials.gov
NCT02774291	Anti-NY ESO-1 mTCR Peripheral Blood Lymphocytes	Early phase 1	3	2023-08-04	HLA-A2 Positive Cells Present, Metastatic Malignant Neoplasm, Metastatic Malignant Neoplasm in the Brain	ALDESLEUKIN, CYCLOPHOSPHAMIDE, FLUDARABINE PHOSPHATE	Its record names the disease	ClinicalTrials.gov
NCT01441115	ECI301 and Radiation for Advanced or Metastatic Cancer	Phase 1	2	2021-12-28	Cancer, Neoplasm Metastasis, Radiation Oncology, Neoplasm, Metastasis	NAGRESTIPEN	Its record names the disease	ClinicalTrials.gov
NCT03009058	Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer	Phase 1/2	2	2024-11-25	Metastatic Cancer	ATEZOLIZUMAB, CAPECITABINE, CETUXIMAB, CYCLOPHOSPHAMIDE, FLUOROURACIL, FOLINIC ACID, GEMCITABINE, IPILIMUMAB, IRINOTECAN, NIVOLUMAB, OXALIPLATIN, PACLITAXEL, PEMBROLIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT00924287	Gene Therapy Using Anti-Her-2 Cells to Treat Metastatic Cancer	Phase 1/2	1	2012-02-14	Metastatic Cancer	ALDESLEUKIN	Its record names the disease	ClinicalTrials.gov
NCT05078047	Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO	Phase 3	646		Lung Cancer Metastatic, Renal Cell Carcinoma, Head and Neck Cancer, Triple Negative Breast Cancer, Merkel Cell Carcinoma, Hepatocellular Carcinoma, Melanoma, Urothelial Carcinoma, Colorectal Carcinoma With Microsatellite Instability, Esophageal Squamous Cell Carcinoma, Endometrial Carcinoma, Cervical Cancer, Gastric/Gastro-esophageal Junction/Esophageal Adenocarcinoma, Basal Cell Carcinoma, Squamous Skin Carcinoma	ATEZOLIZUMAB	Its record names the disease	ClinicalTrials.gov

1 to 10 of 36

See all 36 trials

Comparisons in its trials5

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Abemaciclib 150 mg vs Abemaciclib 200 mg: Number of Participants With One or More Drug Related Adverse Events	12 of 12	13 of 13	25	NCT02919696	Trial comparisons
Abemaciclib 150 mg vs Abemaciclib 200 mg: deaths from any cause	6 of 12	1 of 13	25	NCT02919696	Trial comparisons
Abemaciclib 150 mg vs Abemaciclib 200 mg: serious adverse events	2 of 12	4 of 13	25	NCT02919696	Trial comparisons
Anti-p53 TCR PBL + DC + IL-2: Melanoma/RCC vs Anti-p53 TCR PBL + DC + IL-2: Other Histology: Number of Participants With Adverse Events	2 of 2	1 of 1	3	NCT00704938	Trial comparisons
Anti-p53 TCR PBL + DC + IL-2: Melanoma/RCC vs Anti-p53 TCR PBL + DC + IL-2: Other Histology: serious adverse events	0 of 2	0 of 1	3	NCT00704938	Trial comparisons

Papers from its trials10

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
18626572	RESULT	1	PubMed
8368765	RESULT	1	PubMed
42140743	DERIVED	1	PubMed
37131154	DERIVED	1	PubMed
33761922	DERIVED	1	PubMed
33593828	DERIVED	1	PubMed
33492568	DERIVED	1	PubMed
30064401	DERIVED	1	PubMed
25432172	DERIVED	1	PubMed
24746841	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0024880

GET https://conductscience.org/api/diseases/v1/MONDO_0024880/drugs?page=2

API reference For AI assistants